Earlier this year, an ad-hoc measure development workgroup was convened to address recent changes in guidelines and evidence that strongly recommend statin use and discourage treatment to target LDL levels for patients at high-risk of developing cardiovascular disease.
After thoughtful and thorough discussion, the workgroup recently completed the redesign of the cholesterol component for the Optimal Diabetes and Vascular Care measures, as well as the associated measure and field specifications. The new component, design and specifications were reviewed and approved by MNCM’s Measurement and Reporting Committee on Wednesday, October 8, 2014.
The changes impact data submission for patients receiving care for dates of service between January 1 and December 31, 2015. This does not impact data submission in 2015 for 2014 dates of service.
Key elements of the redesigned cholesterol component are:
- Focus on any statin use for patients, not prescriptive of dose or intensity.
- Use of a measure calculation algorithm that categorizes patients by risk and appropriateness for statins.
- Alignment with ACC/AHA Cholesterol Management and ICSI Guidelines, as well as a new draft population-based CMS measure. Areas of alignment include no specification of dose, no use of the CV risk calculator and allowed exceptions for statins.For detailed information, please refer to:
More detailed information is available here:
- Memorandum regarding Cholesterol Components for Diabetes and Vascular Care Measures
- Draft Measure and Field Specifications for Redesigned Cholesterol Component
- Measure Algorithm for Redesigned Cholesterol Component (NOTE: The measure algorithm looks complex, but many steps are calculated by the MNCM Data Portal from data elements already being collected.)